Three licensed and three research human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay (ETA) kits were evaluated with a panel of 213 serum or plasma samples which were previously tested by the indirect immunofluorescence method for HTLV-I and -II antibodies. The three research kits were found to be more sensitive and specific than the three licensed kits.
A relatively high rate of antibody to human T-cell lymphotropic virus type II (HTLV-II) has been demonstrated in intravenous drug user (IVDU) populations in various regions in the United States, including California (3, 4, 8, 9 ). An HTLV-I enzyme immunoassay (EIA) screening test is usually used to test for antibody, but HTLV-T and HTLV-II share cross-reacting antigens, and the EIA can not differentiate antibodies to these two agents. In studies done by techniques which can distinguish HTLV-T from HTLV-TT infection, such as the polymerase chain reaction, it has been confirmed that the majority of antibody found in IVDU populations in the United States is to HTLV-II (4, (6) (7) (8) (9) .
In the present study, we evaluated six commercial HTLV-I EIA kits in their configurations as of September The kits were evaluated with a panel of 213 serum or plasma samples which were screened by immunofluorescence assay (IFA) on both HTLV-I-and HTLV-II-infected cells as described previously (3) . The panel consisted of 35 IFA-negative and 110 IFA-positive samples from patients attending drug treatment centers and 66 IFA-negative and 2 IFA-positive samples from blood bank donors. Specimens that gave discrepant results between EIA and IFA were tested by Western immunoblot (WB) and radioimmunoprecipitation (RIPA), if necessary, as described previously (2); and the reactions were interpreted as positive, negative, or indeterminate according to the criteria of the Centers for Disease Control (1) . Table 1 provides results of EIA, IFA, and the confirmatory tests. The three research kits detected all 112 samples that were positive by IFA. Only 102, 62, and 58 of these samples were reactive with the Abbott, DuPont, and CPI kits, respectively.
Of the 101 IFA-negative specimens, 3 were reactive with * Corresponding author.
the OTC and Abbott kits; 4 were reactive with the CAMB kit; and 9, 17, and 27 were reactive with the CPI, GSC, and DuPont kits, respectively. The majority of these discrepant specimens were found to be negative by WB, although a few displayed core band reactions which were interpreted as indeterminate or had an insufficient quantity for testing. The results of this study indicate that there are appreciable differences in the sensitivities and specificities of these commercial HTLV-T EIA kits. These EIA kits are designed to detect antibody to HTLV-I. Kline 
